Open Letter to Noventia
Dear Noventia Pharma Team,
We are families affected by Lafora disease who are holding on to hope through your work. Your dedication to developing a treatment for Lafora means everything to us. We were excited when you shared the news of the ION283 license purchase and your intentions to create a clinical trial last year, but we are anxiously awaiting more details. We know that any future progress with ION283 will come from your company, so we kindly request a public update on what is next for the drug’s development after the safety study at UTSW.
As you know, the current ION283 safety study includes only 10 children. While we are grateful this study is happening, many more families were heartbroken to learn our children could not participate. These families are now left waiting, watching their children’s condition progress, and praying for the next opportunity. We are counting on Noventia to help make that opportunity possible.
For many of us, your work is the only hope we have left. Our children do not have time to wait. Lafora disease is aggressive and unforgiving—we are pleading for a chance to save our children’s lives. We desperately urge Noventia to share your plans and move forward quickly with a clinical trial or expanded access program so more children can receive this potentially life-saving treatment. You have our full support in this mission, and we are willing to assist however we can.
We would greatly appreciate it if you could share any updates with us or join our community for a Q&A. Some of our questions include:
- How soon would expanded access be available for those not included in the trial?
- What will be the initial phase of the clinical trial conducted by Noventia?
- Which international sites will be involved?
- Are those sites accredited to conduct a clinical trial?
We look forward to your prompt response and a clear outline of Noventia’s intentions regarding ION283. We are grateful for everything you do for the rare disease community and remain hopeful that Noventia will act swiftly to help more families in this fight against Lafora disease.
With hope,
The Lafora patient community
Patient organizations:
Lafora warriors and their families:
Hanifa Ishaque
Maggie Blatz
Anthony Caycho
Durmisevic Amar
Camila Bicca Oliveira
Caroline Bicca Oliveira
Prakash
Dr. Sagheer Hanif
Zarana Rathod
Tammie
Gonzalo Bruquetas
أم حسین الطباطبائي
Samy Sharif
Gladi Gidanian
Bilal Bhat
Bies Mahabier
Jamie Hennon
Marianne Rodriquez
Marina Weiss & Gajic Family
Georgianna
Spiros Georgakis
Paola Pacca
Romina Varesi
Silvana Parlato
Sami Memon
Marija Mrvosevic
Colleen Baumgartner-Hirsh
Simona Fochetti
Joan Monda
Babeth Letort
Jenifer Merriam
Recai yıldız
Marija Novakovic
Veronique Gadomski
Pierre Gadomski
Nuray yıldız
Fatos Malaj
Maha Hashim Alansari
Carmine Lettieri
Moniqueca Barfield
Jette Daubjerg
Elpida Georgaki








Sophie Stein is a rising senior at Cornell University pursuing a degree in Human Development. She has a special interest in medical research.
Sara Gerber is a genetic counseling graduate student at Stanford University. She is passionate about rare disease research and advocacy, bioethics, and public health.
Sally Leung graduated from UC Irvine with a B.A. in Public Health Policy. She is excited to start a Master’s in Public Health program and is interested in exploring how healthcare inequities affect chronic and infectious diseases in medically underserved communities
Jeremiah Paul is a rising senior at the University of Miami, studying Business and Computer Science. Diagnosed with a chronic illness at a young age, he understands the challenges faced by the Lafora community and wants to use his skills to support our cause.
Vaishali Jain is a rising junior
Samy Sharif is starting medical school in the fall and is eager to help with Lafora advocacy efforts. He wants to make a lasting impact by creating accessible resources and sharing powerful stories.
Jhanavi Kotian is a senior at San Jose State University, majoring in Biological Sciences. She is eager to bridge the gap between families and the scientific community through effective, compassionate communication.
Anna Gould is a rare disease advocate who graduated from
Kait Fedor has a passion for nonprofit development and a drive to raise funds and support for the Lafora disease community. She earned her MS in Nonprofit Management and Philanthropy from Bay Path University in 2024. 

A Happy Childhood
Almost a year later, while participating in the Scouts program she loved, Mathilde had another episode where she was also uncontactable for over an hour. This time, she experienced muscle jerks in her right arm. She had another EEG, which showed epileptic activity around the same time as the results of the first one appeared.



